Factors that influence bispecific antibodies’ placement on formularies

Teclistamab has a clear advantage because it was the first bispecific antibody to be approved, said Adams. Route of administration, the pace of the step-up dosing, the relationship with community providers and risk evaluation and mitigation strategies (REMS) requirements all factor into formulary decisions, she said. Payers may start preferring one bispecific antibody over another because the efficacy among them is similar, Adams said.